)
)
)
Lynk Pharmaceuticals
Lynk is a clinical-stage company focusing on autoimmune indications. Differentiated assets:
LNK01001: Best-in-Class JAK1i (Ph3) for I&I,
LNK01004: Tissue-restricted JAKi for Derm (Ph2)
LNK-10002244: Systemic TYK2i for Type 1 diabetes & IBD (IND enabling)
LNK-011: Novel oral VAV1 degraders for various autoimmune indications (PCC candidates)
*We are not accepting invitations from service providers at this time.
Address
ArlingtonMassachusetts
United States
)
){kind=logo}
)
){kind=logo}
){kind=logo}
)
)
)
)